Innate Pharma S.A. (LON:0EVI)

Market Cap	115.42M -15.1%
Revenue (ttm)	10.83M -62.6%
Net Income	-39.47M
EPS	-0.47
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4
Average Volume	9,635
Open	1.420
Previous Close	1.398
Day's Range	1.420 - 1.420
52-Week Range	1.394 - 2.450
Beta	0.57
RSI	37.11
Earnings Date	Mar 26, 2026

About Innate Pharma

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 174
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0EVI

Financial Performance

In 2024, Innate Pharma's revenue was 20.12 million, a decrease of -67.36% compared to the previous year's 61.64 million. Losses were -49.47 million, 553.5% more than in 2023.

Financial numbers in EUR